Clinical Trial: Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840119) titled 'Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers' on Feb. 05.

Brief Summary: This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 x CD3 ImmTAC(R) Bispecific Protein) as a single agent and in combination with other therapies in HLA-A*02:01-positive participants with selected advanced cancers.

Study Start Date: Jan. 10, 2024

Study Type: INTERVENTIONAL

Condition: Cancer HLA-A*02:01-positive

Intervention: DRUG: IMC-R117C

IV infusion

DRUG: Chemotherapy drug

IV infusion

DRUG: Chemotherapy drug

oral

DRUG: Kinase inhibitor

oral

DRUG: Antiangiogenic Agent

IV infusion

DR...